Funding for this research was provided by:
Innovative Medicines Initiative Joint Undertaking (115546)
Text and Data Mining valid from 2018-07-06
Received: 21 September 2017
Accepted: 27 June 2018
First Online: 6 July 2018
Ethics approval and consent to participate
: These were analyses, modeling and simulations using data from the SOHO database, therefore neither ethics approval nor consent to participate were required.
: Not applicable.
: HK, SF, JM, and CN are employed by Analytica Laser, an independent private research organisation funded by multiple clients across the pharmaceutical industry, regulatory agencies or research entities, private or otherwise. Analytica Laser has no commercial interests in any of the products studied. HK, SF, JM, and CN declare no other conflicts of interest besides having received a grant from the Innovative Medicines Initiative Joint Undertaking during the conduct of the study. MZA was employed as a post-doc by Novo Nordisk A/S during the conduct of the study; he declares no other conflict of interest. OE declares having received a grant from the Innovative Medicines Initiative Joint Undertaking during the conduct of the study; he reports no other conflict of interest. MB is an employee and shareholder of Eli Lilly; he has no other conflicts of interest. JMH is employed by the University of Barcelona; he declares no other conflicts of interest. LA is chairman and stock owner in Analytica Laser.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.